MEMORIAL DAY OFFER 50% OFF Premium Subscription Order Now MEMORIAL DAY 50% OFF Subscription >>

No Pain, No Gain.Week 21 On Stock Market Click to watch.

Cara Therapeutics Stock Forecast

NASDAQ:CARA BUY SELL

$8.24 (2.87%)

Volume: 281.997k

Closed: May 27, 2022

Hollow Logo Score: -5.182

Cara Therapeutics Stock Forecast

BUY SELL NASDAQ:CARA
$8.24 (2.87%)

Volume: 281.997k

Closed: May 27, 2022

Score Hollow Logo -5.182

Cara Therapeutics Company Profile

1 Parrott Drive

Shelton CT 06484

203-567-1500

www.caratherapeutics.com

Industry: Biotechnology

Sector: Healthcare

Cara Therapeutics

Description

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system. Its lead product candidate includes I.V. CR845, which is in Phase III clinical trials for the treatment acute postoperative pain in adult patients, as well as completed Phase II clinical trials for the treatment of uremic pruritus disease. The company is also developing Oral CR845, which is in Phase IIa clinical trials for the treatment of moderate-to-severe acute and chronic pain; and CR701, which is in preclinical trial stage for treating neuropathic and inflammatory pain. It has licensing agreements with Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize products containing CR845 in South Korea; and Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Shelton, Connecticut.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE